Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and ...
Recursion Pharmaceuticals, Inc. (RXRX), the self-styled "clinical-stage TechBio company with a mission to decode biology to radically improve lives" (Source: 2025 annual report/10-K filing), reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results